Zura Bio Limited Class A Ordinary Shares (ZURA NASDAQ) stock market data APIs
$2.03
0.08(4.1%)
as of January 14, 2025
Zura Bio Limited Class A Ordinary Shares Financial Data Overview
Price chart is built with
Anychart
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Prev. Close
1.95
Open
2.03
Volume
299 K
High
2.03
Low
1.91
52 wk Range
1.86-6.35
Market Cap
296 M
P/E Ratio
7.9474
Shares Outstanding
63 774 K
Revenue
0
EPS
-0.26
Beta
0.135
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zura Bio Limited Class A Ordinary Shares data using free add-ons & libraries
Get Zura Bio Limited Class A Ordinary Shares Fundamental Data
Zura Bio Limited Class A Ordinary Shares Fundamental data includes:
- Net Revenue: 0
- EBITDA: 0
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.12
Get Zura Bio Limited Class A Ordinary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zura Bio Limited Class A Ordinary Shares News
New
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Sagimet Biosciences Inc. SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid ...
3 Undervalued Biotech Stocks With Breakout Potential
Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies. W...
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. In fact, according to Grand View Research, biotech could be worth about $3.88 trillion b...
Zura Bio Limited Announces Share Redemptions and Lock-up Agreement
SAN DIEGO, March 27, 2023--(BUSINESS WIRE)--As previously announced on March 21, 2023, Zura Bio Limited ("Zura"), a multi-asset clinical-stage biotechnology company focused on developing novel medicin...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
